Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/ Randomized Phase II Study of Gemcitabine Plus Erlotinib Plus MK-0646; Gemcitabine Plus MK-0646 and Gemcitabine Plus Erlotinib for Patients With Advanced Pancreatic Cancer (IISP#33337)

NCT00769483 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT00769483
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00769483 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/ Randomized Phase II Study of Gemcitabine Plus Erlotinib Plus MK-0646; Gemcitabine Plus MK-0646 and Gemcitabine Plus Erlotinib for Patients With Advanced Pancreatic Cancer (IISP#33337)
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1/2
Overall status
Completed
Start date
November 13, 2008
Completion date
September 1, 2020
Enrollment
81 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma, pancreatic cancer